United States Multiple Sclerosis Drugs Market Report & Forecast 2021-2027

United States Multiple Sclerosis Drugs Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Multiple Sclerosis Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Multiple Sclerosis Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Multiple Sclerosis Drugs Overall Market Size
2.1 United States Multiple Sclerosis Drugs Market Size: 2021 VS 2027
2.2 United States Multiple Sclerosis Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Multiple Sclerosis Drugs Sales: 2016-2027
3 Company Landscape
3.1 Top Multiple Sclerosis Drugs Players in United States Market
3.2 Top United States Multiple Sclerosis Drugs Companies Ranked by Revenue
3.3 United States Multiple Sclerosis Drugs Revenue by Companies
3.4 United States Multiple Sclerosis Drugs Sales by Companies
3.5 United States Multiple Sclerosis Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Multiple Sclerosis Drugs Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Multiple Sclerosis Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Sclerosis Drugs Players in United States Market
3.8.1 List of Tier 1 Multiple Sclerosis Drugs Companies in United States
3.8.2 List of Tier 2 and Tier 3 Multiple Sclerosis Drugs Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Multiple Sclerosis Drugs Market Size Markets, 2021 & 2027
4.1.2 Injectable Medications
4.1.3 Oral Medications
4.1.4 Others
4.2 By Type - United States Multiple Sclerosis Drugs Revenue & Forecasts
4.2.1 By Type - United States Multiple Sclerosis Drugs Revenue, 2016-2021
4.2.2 By Type - United States Multiple Sclerosis Drugs Revenue, 2022-2027
4.2.3 By Type - United States Multiple Sclerosis Drugs Revenue Market Share, 2016-2027
4.3 By Type - United States Multiple Sclerosis Drugs Sales & Forecasts
4.3.1 By Type - United States Multiple Sclerosis Drugs Sales, 2016-2021
4.3.2 By Type - United States Multiple Sclerosis Drugs Sales, 2022-2027
4.3.3 By Type - United States Multiple Sclerosis Drugs Sales Market Share, 2016-2027
4.4 By Type - United States Multiple Sclerosis Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Multiple Sclerosis Drugs Market Size, 2021 & 2027
5.1.2 Adults
5.1.3 Children
5.2 By Application - United States Multiple Sclerosis Drugs Revenue & Forecasts
5.2.1 By Application - United States Multiple Sclerosis Drugs Revenue, 2016-2021
5.2.2 By Application - United States Multiple Sclerosis Drugs Revenue, 2022-2027
5.2.3 By Application - United States Multiple Sclerosis Drugs Revenue Market Share, 2016-2027
5.3 By Application - United States Multiple Sclerosis Drugs Sales & Forecasts
5.3.1 By Application - United States Multiple Sclerosis Drugs Sales, 2016-2021
5.3.2 By Application - United States Multiple Sclerosis Drugs Sales, 2022-2027
5.3.3 By Application - United States Multiple Sclerosis Drugs Sales Market Share, 2016-2027
5.4 By Application - United States Multiple Sclerosis Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Biogen
6.1.1 Biogen Corporation Information
6.1.2 Biogen Overview
6.1.3 Biogen Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.1.4 Biogen Multiple Sclerosis Drugs Product Description
6.1.5 Biogen Recent Developments
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Overview
6.2.3 Sanofi Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.2.4 Sanofi Multiple Sclerosis Drugs Product Description
6.2.5 Sanofi Recent Developments
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Overview
6.3.3 Novartis Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.3.4 Novartis Multiple Sclerosis Drugs Product Description
6.3.5 Novartis Recent Developments
6.4 Teva
6.4.1 Teva Corporation Information
6.4.2 Teva Overview
6.4.3 Teva Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.4.4 Teva Multiple Sclerosis Drugs Product Description
6.4.5 Teva Recent Developments
6.5 Merck KGaA
6.5.1 Merck KGaA Corporation Information
6.5.2 Merck KGaA Overview
6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.5.4 Merck KGaA Multiple Sclerosis Drugs Product Description
6.5.5 Merck KGaA Recent Developments
6.6 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Overview
6.6.3 Bayer Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.6.4 Bayer Multiple Sclerosis Drugs Product Description
6.6.5 Bayer Recent Developments
6.7 ACORDA
6.7.1 ACORDA Corporation Information
6.7.2 ACORDA Overview
6.7.3 ACORDA Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.7.4 ACORDA Multiple Sclerosis Drugs Product Description
6.7.5 ACORDA Recent Developments
6.8 Mallinckrodt
6.8.1 Mallinckrodt Corporation Information
6.8.2 Mallinckrodt Overview
6.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales and Revenue in United States Market (2016-2021)
6.8.4 Mallinckrodt Multiple Sclerosis Drugs Product Description
6.8.5 Mallinckrodt Recent Developments
7 United States Multiple Sclerosis Drugs Production Capacity, Analysis
7.1 United States Multiple Sclerosis Drugs Production Capacity, 2016-2027
7.2 Multiple Sclerosis Drugs Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Multiple Sclerosis Drugs Supply Chain Analysis
9.1 Multiple Sclerosis Drugs Industry Value Chain
9.2 Multiple Sclerosis Drugs Upstream Market
9.3 Multiple Sclerosis Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Multiple Sclerosis Drugs Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Multiple Sclerosis Drugs in United States Market
Table 2. Top Multiple Sclerosis Drugs Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Multiple Sclerosis Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Multiple Sclerosis Drugs Revenue Share by Companies, 2016-2021
Table 5. United States Multiple Sclerosis Drugs Sales by Companies, (K Units), 2016-2021
Table 6. United States Multiple Sclerosis Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Multiple Sclerosis Drugs Price (2016-2021) & (USD/Unit)
Table 8. Manufacturers Multiple Sclerosis Drugs Product Type
Table 9. List of Tier 1 Multiple Sclerosis Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Multiple Sclerosis Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Injectable Medications
Table 12. Major Manufacturers of Oral Medications
Table 13. By Type - United States Multiple Sclerosis Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Multiple Sclerosis Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Multiple Sclerosis Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Multiple Sclerosis Drugs Sales (K Units), 2016-2021
Table 17. By Type - United States Multiple Sclerosis Drugs Sales (K Units), 2022-2027
Table 18. By Application - United States Multiple Sclerosis Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Multiple Sclerosis Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Multiple Sclerosis Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Multiple Sclerosis Drugs Sales (K Units), 2016-2021
Table 22. By Application - United States Multiple Sclerosis Drugs Sales (K Units), 2022-2027
Table 23. Biogen Corporation Information
Table 24. Biogen Description and Major Businesses
Table 25. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 26. Biogen Multiple Sclerosis Drugs Product
Table 27. Biogen Recent Developments
Table 28. Sanofi Corporation Information
Table 29. Sanofi Description and Major Businesses
Table 30. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 31. Sanofi Multiple Sclerosis Drugs Product
Table 32. Sanofi Recent Developments
Table 33. Novartis Corporation Information
Table 34. Novartis Description and Major Businesses
Table 35. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 36. Novartis Multiple Sclerosis Drugs Product
Table 37. Novartis Recent Developments
Table 38. Teva Corporation Information
Table 39. Teva Description and Major Businesses
Table 40. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 41. Teva Multiple Sclerosis Drugs Product
Table 42. Teva Recent Developments
Table 43. Merck KGaA Corporation Information
Table 44. Merck KGaA Description and Major Businesses
Table 45. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 46. Merck KGaA Multiple Sclerosis Drugs Product
Table 47. Merck KGaA Recent Developments
Table 48. Bayer Corporation Information
Table 49. Bayer Description and Major Businesses
Table 50. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 51. Bayer Multiple Sclerosis Drugs Product
Table 52. Bayer Recent Developments
Table 53. ACORDA Corporation Information
Table 54. ACORDA Description and Major Businesses
Table 55. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 56. ACORDA Multiple Sclerosis Drugs Product
Table 57. ACORDA Recent Developments
Table 58. Mallinckrodt Corporation Information
Table 59. Mallinckrodt Description and Major Businesses
Table 60. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 61. Mallinckrodt Multiple Sclerosis Drugs Product
Table 62. Mallinckrodt Recent Developments
Table 63. Multiple Sclerosis Drugs Production Capacity (K Units) of Key Manufacturers in United States Market, 2019-2021 (K Units)
Table 64. United States Multiple Sclerosis Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 65. Multiple Sclerosis Drugs Market Opportunities & Trends in United States Market
Table 66. Multiple Sclerosis Drugs Market Drivers in United States Market
Table 67. Multiple Sclerosis Drugs Market Restraints in United States Market
Table 68. Multiple Sclerosis Drugs Raw Materials
Table 69. Multiple Sclerosis Drugs Raw Materials Suppliers in United States Market
Table 70. Typical Multiple Sclerosis Drugs Downstream
Table 71. Multiple Sclerosis Drugs Downstream Clients in United States Market
Table 72. Multiple Sclerosis Drugs Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Multiple Sclerosis Drugs Product Picture
Figure 2. Multiple Sclerosis Drugs Segment by Type
Figure 3. Multiple Sclerosis Drugs Segment by Application
Figure 4. United States Multiple Sclerosis Drugs Market Overview: 2020
Figure 5. United States Multiple Sclerosis Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Multiple Sclerosis Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Multiple Sclerosis Drugs Sales in United States Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Multiple Sclerosis Drugs Revenue in 2020
Figure 9. Injectable Medications Product Picture
Figure 10. Oral Medications Product Picture
Figure 11. Others Product Picture
Figure 12. By Type - United States Multiple Sclerosis Drugs Sales Market Share, 2016-2027
Figure 13. By Type - United States Multiple Sclerosis Drugs Revenue Market Share, 2016-2027
Figure 14. By Type - United States Multiple Sclerosis Drugs Price (USD/Unit), 2016-2027
Figure 15. Adults
Figure 16. Children
Figure 17. By Application - United States Multiple Sclerosis Drugs Sales Market Share, 2016-2027
Figure 18. By Application - United States Multiple Sclerosis Drugs Revenue Market Share, 2016-2027
Figure 19. By Application - United States Multiple Sclerosis Drugs Price (USD/Unit), 2016-2027
Figure 20. Biogen Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 21. Sanofi Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 22. Novartis Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Teva Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Merck KGaA Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Bayer Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. ACORDA Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Mallinckrodt Multiple Sclerosis Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. United States Multiple Sclerosis Drugs Production Capacity (K Units), 2016-2027
Figure 29. Multiple Sclerosis Drugs Industry Value Chain
Figure 30. Marketing Channels

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Fingolimod Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Multiple Sclerosis Drugs Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78

The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......

Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118

Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......

Fingolimod - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77

The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......

Global Fingolimod Market Research Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Global Fingolimod Professional Survey Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024

Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96

This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......

Global Multiple Sclerosis Drugs Market Research Report 2023

Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......

Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122

Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs